Literature DB >> 32504882

Sickle cell disease clinical phenotypes in Nigeria: A preliminary analysis of the Sickle Pan Africa Research Consortium Nigeria database.

Hezekiah Isa1, Samuel Adegoke2, Anazoeze Madu3, Abdul-Aziz Hassan4, Chinatu Ohiaeri5, Reuben Chianumba1, Biobele Brown6, Emmanuel Okocha7, Ngozi Ugwu8, Ijeoma Diaku-Akinwumi9, Titilope Adeyemo10, Aisha Kuliya-Gwarzo11, Livingstone Dogara12, Haliru Lawal12, Yohanna Tanko1, Adama Ladu13, Umar Kangiwa14, Lilian Ekwem15, Seyi Oniyangi16, Tambi Wakama17, Domic Umoru18, Olaniyi Olanrewaju19, Norah Akinola20, Uche Nnebe-Agumadu21, Samuel Asala1, Adekunle Adekile22, John Olaniyi6, Raphael Sangeda23, Obiageli Nnodu24.   

Abstract

BACKGROUND/
OBJECTIVE: Sickle cell disease (SCD) is a monogenic disease with multiple phenotypic expressions. Previous studies describing SCD clinical phenotypes in Nigeria were localized, with limited data, hence the need to understand how SCD varies across Nigeria.
METHOD: The Sickle Pan African Research Consortium (SPARCO) with a hub in Tanzania and collaborative sites in Tanzania, Ghana and Nigeria, is establishing a single patient-consented electronic database with a target of 13,000 SCD patients. In collaboration with the Sickle Cell Support Society of Nigeria, 20 hospitals, with paediatric and adult SCD clinics, are participating in patient recruitment. Demographic and clinical information, collected with uniform case report forms, were entered into Excel spreadsheets and uploaded into Research Electronic Data Capture software by trained data clerks and frequency tables generated. RESULT: Data were available on 3622 patients enrolled in the database, comprising 1889 (52.9%) females and 1434 (39.6%) children ≤15 years. The frequencies of Hb SS, Hb SC and Hb Sβ thalassemia in this data set were 97.5%, 2.5% and 0% respectively. Sixty percent, 23.8%, 5.9%, 4.8% and 2.5% have had bone pain crisis, dactylitis, acute chest syndrome, priapism and stroke respectively. The most frequent chronic complications were: leg ulcers (6.5%), avascular necrosis of bone (6.0%), renal (6.3%) and pulmonary hypertension (1.1%). Only 13.2% had been hospitalized while 67.5% had received blood transfusion.
CONCLUSION: These data on the spectrum of clinical phenotypes of SCD are useful for planning, improving the management of SCD across Nigeria and provide a foundation for genomic research on SCD.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clinical phenotypes; Haemoglobinopathy registry; Nigeria; Sickle cell disease

Mesh:

Year:  2020        PMID: 32504882      PMCID: PMC9509704          DOI: 10.1016/j.bcmd.2020.102438

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   2.372


  33 in total

1.  Sickle cell anaemia in Nigeria: a comparison between Benin and Lagos.

Authors:  G Akenzua; O Akinyanju; A Kulozik; S Whitehead; J Morris; B E Serjeant; G Serjeant
Journal:  Afr J Med Med Sci       Date:  1994-06

2.  Abnormal haemoglobins in the Sudan savanna of Nigeria. I. Prevalence of haemoglobins and relationships between sickle cell trait, malaria and survival.

Authors:  A F Fleming; J Storey; L Molineaux; E A Iroko; E D Attai
Journal:  Ann Trop Med Parasitol       Date:  1979-04

3.  Leg ulceration in sickle cell anemia.

Authors:  G R Serjeant
Journal:  Arch Intern Med       Date:  1974-04

4.  Avascular necrosis of the hip in children with sickle cell disease and high Hb F: magnetic resonance imaging findings and influence of alpha-thalassemia trait.

Authors:  A D Adekile; R Gupta; F Yacoub; T Sinan; M Al-Bloushi; M Z Haider
Journal:  Acta Haematol       Date:  2001       Impact factor: 2.195

5.  Stroke prevalence amongst sickle cell disease patients in Nigeria: a multi-centre study.

Authors:  Madu Anazoeze Jude; Galadanci Najiba Aliyu; Aisha Mohammed Nalado; Kangiwa Umar Garba; Fowodu O Florence; Ahmed Hassan; Marcus Inyama; Oluwaseun Akinpelu; Nwagha Theresa; Ibegbulam Obike Godswill; Ocheni Sunday; Emodi Ifeoma; Ikefuna Anthony; Chukwu Batholomew; Okocha E Chide; Orkuma Joseph; Iheanacho Malachy; Kaladada Korubo; Anike Uchenna Sabastine; Agu Kingsley; Charles Nonyelu; Angela Ugwu; Augustin Duru; Chukwudi Anigbo; Alozie Eze; Awele Chukwurah; Uchenna Ololo; Caroline Omoti; Obineche Agwu; Okpala Iheanyi
Journal:  Afr Health Sci       Date:  2014-06       Impact factor: 0.927

6.  Avascular necrosis in sickle cell (homozygous S) patients: predictive clinical and laboratory indices.

Authors:  A J Madu; A K Madu; G K Umar; K Ibekwe; A Duru; A O Ugwu
Journal:  Niger J Clin Pract       Date:  2014 Jan-Feb       Impact factor: 0.968

7.  Avascular necrosis of the femoral head in sickle cell disease in Nigeria: a retrospective study.

Authors:  A L Akinyoola; I A Adediran; C M Asaleye
Journal:  Niger Postgrad Med J       Date:  2007-09

8.  The painful crisis of homozygous sickle cell disease: clinical features.

Authors:  G R Serjeant; C D Ceulaer; R Lethbridge; J Morris; A Singhal; P W Thomas
Journal:  Br J Haematol       Date:  1994-07       Impact factor: 6.998

9.  Observations on the natural history of dactylitis in homozygous sickle cell disease.

Authors:  M C Stevens; M Padwick; G R Serjeant
Journal:  Clin Pediatr (Phila)       Date:  1981-05       Impact factor: 1.168

10.  A survey of genetic fetal-haemoglobin modifiers in Nigerian patients with sickle cell anaemia.

Authors:  Titilope A Adeyemo; Oyesola O Ojewunmi; Idat A Oyetunji; Helen Rooks; David C Rees; Adebola O Akinsulie; Alani S Akanmu; Swee Lay Thein; Stephan Menzel
Journal:  PLoS One       Date:  2018-06-07       Impact factor: 3.240

View more
  5 in total

1.  The Epidemiology of Neurological Complications in Adults With Sickle Cell Disease: A Retrospective Cohort Study.

Authors:  Chinedu Maduakor; Vafa Alakbarzade; Yezen Sammaraiee; Angeliki Vakrinou; Alina Corobana; Julia Sikorska; Elizabeth Rhodes; Anthony C Pereira
Journal:  Front Neurol       Date:  2021-12-15       Impact factor: 4.003

2.  Outcome of Hydroxyurea Use in SCD and Evaluation of Patients' Perception and Experience in Nigeria.

Authors:  Reuben Ikechukwu Chianumba; Akinyemi O D Ofakunrin; Jack Morrice; Olaniyi Olanrewaju; Oluseyi Oniyangi; Aisha Kuliya-Gwarzo; Uche Nnebe-Agumadu; Hezekiah Alkali Isa; Obiageli Eunice Nnodu
Journal:  Front Genet       Date:  2022-03-24       Impact factor: 4.772

3.  Establishing a Sickle Cell Disease Registry in Africa: Experience From the Sickle Pan-African Research Consortium, Kumasi-Ghana.

Authors:  Vivian Paintsil; Evans Xorse Amuzu; Isaac Nyanor; Emmanuel Asafo-Adjei; Abdul Razak Mohammed; Suraj Abubakar Yawnumah; Yaa Gyamfua Oppong-Mensah; Samuel Blay Nguah; Paul Obeng; Elliot Eli Dogbe; Mario Jonas; Victoria Nembaware; Gaston Mazandu; Kwaku Ohene-Frempong; Ambroise Wonkam; Julie Makani; Daniel Ansong; Alex Osei-Akoto
Journal:  Front Genet       Date:  2022-02-24       Impact factor: 4.599

4.  Skills Capacity Building For Health Care Services and Research Through the Sickle Pan African Research Consortium.

Authors:  Obiageli Eunice Nnodu; Alex Osei-Akoto; Victoria Nembaware; Jill Kent; Maxwell Nwegbu; Irene Minja; Gaston Kuzamunu Mazandu; Julie Makani; Ambroise Wonkam
Journal:  Front Genet       Date:  2022-06-15       Impact factor: 4.772

Review 5.  Stroke in Africa: profile, progress, prospects and priorities.

Authors:  Rajesh N Kalaria; Mayowa O Owolabi; Rufus O Akinyemi; Bruce Ovbiagele; Olaleye A Adeniji; Fred S Sarfo; Foad Abd-Allah; Thierry Adoukonou; Okechukwu S Ogah; Pamela Naidoo; Albertino Damasceno; Richard W Walker; Adesola Ogunniyi
Journal:  Nat Rev Neurol       Date:  2021-09-15       Impact factor: 42.937

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.